SeraNovo and Équilibre enter licence agreement

15-Nov-2021

“We are thrilled to enter into this license agreement with Équilibre and progress another poorly water soluble drug candidate into the clinic"

SeraNovo has announced the closing of a license agreement with Équilibre BioPharmaceuticals Corporation, a biopharmaceutical company engaged in the research and development of small molecules in the field of neuroscience. Under the agreement, the companies plan to expand their existing collaboration and jointly develop a breakthrough product.

Sign up for your free email newsletter

Niall Hodgins, CEO of SeraNovo said: “We are thrilled to enter into this license agreement with Équilibre and progress another poorly water soluble drug candidate into the clinic using our deep eutectic solvent formulation platform. This agreement is a great step to broaden our customer base in North America and into the neurology field. SeraNovo are looking forward to many fruitful collaborations in these important markets.”

Companies